Pharmagen, Inc. (PHRX) Stock

About Pharmagen, Inc.

Pharmagen, Inc., a pharmaceutical company located in Silver Spring, Maryland, operates primarily as a distributor within the U.S. healthcare market. It provides a diverse range of specialty drugs to various medical clients, including hospitals, acute care centers, surgical facilities, and other healthcare practitioners nationwide. The company's offerings encompass sourcing and distributing specialty pharmaceuticals, blood plasma derivatives, unique medical products, vaccines, anti-infectives, and often hard-to-find medications. A key area of its expertise lies in plasma derivatives, which are vital for managing severe conditions such as cancer, hemophilia, rheumatoid arthritis, multiple sclerosis, blood disorders, hepatitis, and HIV. Additionally, Pharmagen supplies specialized products designed to treat respiratory, oncological, cardiovascular, and hormonal ailments. Beyond its core distribution activities, Pharmagen also produces and sells its own health supplements, notably Clotamin, an over-the-counter multivitamin formulated specifically for individuals undergoing Warfarin therapy. The company further serves its existing customers by supplying traditional pharmaceuticals, including a variety of antibiotics, vaccines, and other oral and injectable medicines. With a specialized focus on drug formulation, Pharmagen Inc. adopted its current name in January 2013, having previously operated as Sunpeaks Ventures, Inc.

Pharmagen, Inc. (PHRX) stock trades at $0.00 with a market capitalization of $517. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Pharmagen, Inc. generates a return on equity (ROE) of 85.12% — well above the market average, a sign of a high-quality business, return on capital employed of 31.67%, an operating margin of -31.11%, a net profit margin of -133.10%.

Official website: www.pharmageninc.com